KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins

Gut

Volumn 64, Issue 9, 2015, Pages 1434-1443

  Marrone, Giusi ^a   Maeso Díaz, Raquel ^a   García Cardena, Guillermo ^b   Abraldes, Juan G ^a   García Pagán, Juan Carlos ^a   Bosch, Jaime ^a   Gracia Sancho, Jordi ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; KRUPPEL LIKE FACTOR 2; PROCOLLAGEN; SIMVASTATIN; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN; ANTIFIBRINOLYTIC AGENT; KLF2 PROTEIN, RAT; KRUPPEL LIKE FACTOR; PROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER BLOOD VESSEL; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; OXIDATIVE STRESS; PARACRINE SIGNALING; PHENOTYPE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL; UPREGULATION; VASCULAR RESISTANCE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; WISTAR RAT;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIVER CIRRHOSIS; MALE; MOLECULAR TARGETED THERAPY; PHENOTYPE; PROTECTIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; SIMVASTATIN; UP-REGULATION;

EID: 84941281919     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308338     Document Type: Article

References (48)

1. Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012;57:458-61.
2. Marrone G, Gracia-Sancho J. Hepatic microcirculation in chronic liver disease. In: Peralta C, Fontana L., eds. Liver failure: etiologies, neurological complications and emerging therapies. Nova Science Publishers, 2013:89-106.
3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
4. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-72.
5. Schuppan D, Popov Y. Hepatic fibrosis: from bench to bedside. J Gastroenterol Hepatol 2002;17(Suppl 3):S300-5.
6. Rombouts K, Kisanga E, Hellemans K, et al. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 2003;38:564-72.
7. Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;121:685-98.
8. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749-55.
9. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl (4) cirrhotic rats. J Hepatol 2007;46:1040-6.
10. Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology 2006;43:485-91.
11. Bieker JJ. Kruppel-like factors: three fingers in many pies. J Biol Chem 2001;276:34355-8.
12. Gracia-Sancho J, Russo L, Garcia-Caldero H, et al. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut 2011;60:517-24.
13. Marrone G, Russo L, Rosado E, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol 2013;58:98-103.
14. Wang W, Zhao C, Zhou J, et al. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS ONE 2013;8:e76538.
15. Motawi TM, Atta HM, Sadik NA, et al. The therapeutic effects of bone marrow-derived mesenchymal stem cells and simvastatin in a rat model of liver fibrosis. Cell Biochem Biophys 2014;68:111-25.
16. Sen Banerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004;199:1305-15.
17. Gracia-Sancho J, Villarreal G Jr, Zhang Y, et al. Flow cessation triggers endothelial dysfunction during organ cold storage conditions: strategies for pharmacologic intervention. Transplantation 2010;90:142-9.
18. Rosado E, Rodriguez-Vilarrupla A, Gracia-Sancho J, et al. Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats. J Cell Mol Med 2012;16:2461-70.
19. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, et al. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 2007;47:220-7.
20. Illa X, Vila S, Yeste J, et al. A novel modular bioreactor to in vitro study the hepatic sinusoid. PLoS ONE 2014;9:e111864.
21. Delgado MG, Gracia-Sancho J, Marrone G, et al. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2013;305:G496-502.
22. Di Pascoli M, Divi M, Rodriguez-Vilarrupla A, et al. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 2013;58:904-10.
23. Moreno M, Gonzalo T, Kok RJ, et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010;51:942-52.
24. Gracia-Sancho J, Laviña B, Rodriguez-Vilarupla A, et al. Evidence against NADPH oxidase modulating hepatic vascular tone in cirrhosis. Gastroenterology 2007;133:959-66.
25. Russo L, Gracia-Sancho J, Garcia-Caldero H, et al. Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. Hepatology 2012;55:921-30.
26. Xie G, Choi SS, Syn WK, et al. Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut 2013;62:299-309.
27. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749-61
28. Liu Y, Sinha S, McDonald OG, et al. Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. J Biol Chem 2005;280:9719-27.
29. Ghiassi-Nejad Z, Hernandez-Gea V, Woodrell C, et al. Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury. Hepatology 2013;57:786-96.
30. Eaton SA, Funnell AP, Sue N, et al. A network of Kruppel-like Factors (Klfs). Klf8 is repressed by Klf3 and activated by Klf1 in vivo. J Biol Chem 2008;283:26937-47.
31. Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242-53.
32. Klein S, Klosel J, Schierwagen R, et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 2012;92:1440-50.
33. Boon RA, Fledderus JO, Volger OL, et al. KLF2 suppresses TGF-beta signaling in endothelium through induction of Smad7 and inhibition of AP-1. Arterioscler Thromb Vasc Biol 2007;27:532-9.
34. Dekker RJ, Boon RA, Rondaij MG, et al. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 2006;107:4354-63.
35. Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010;53:702-12.
36. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
37. Fu Y, Zheng S, Lin J, et al. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73:399-409.
38. De Leve LD, Wang X, Hu L, et al. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol 2004;287:G757-63.
39. Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosci 2008;13:453-61.
40. Habeos IG, Ziros PG, Chartoumpekis D, et al. Simvastatin activates Keap1/Nrf2 signaling in rat liver. J Mol Med (Berl) 2008;86:1279-85.
41. Xu W, Hellerbrand C, Kohler UA, et al. The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. Lab Invest 2008;88:1068-78.
42. Dai G, Vaughn S, Zhang Y, et al. Biomechanical forces in atherosclerosis-resistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/Akt-dependent activation of Nrf2. Circ Res 2007;101:723-3.
43. Fledderus JO, Boon RA, Volger OL, et al. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:1339-46.
44. Gracia-Sancho J, Lavina B, Rodriguez-Vilarupla A, et al. Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 2008;47:1248-56.
45. Mashiba S, Mochida S, Ishikawa K, et al. Inhibition of hepatic stellate cell contraction during activation in vitro by vascular endothelial growth factor in association with upregulation of FLT tyrosine kinase receptor family, FLT-1. Biochem Biophys Res Commun 1999;258:674-8.
46. Gracia-Sancho J, Garcia-Caldero H, Hide D, et al. Simvastatin Maintains Function and Viability of Steatotic Rat Livers Procured for Transplantation. J Hepatol 2013;58:1140-6.
47. La Mura V, Pasarin M, Meireles CZ, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 2013;57:1172-81.
48. Chen JL, Lu XJ, Zou KL, et al. Kruppel-like factor 2 promotes liver steatosis through upregulation of CD36. J Lipid Res 2014;55:32-40.